8.00 - 8.30	VIEWING OF POSTER PRESENTATIONS Posters will be viewed Thursday, November 11 from 12.00 to Friday, November 12, 11.30
8.30 - 9.25	CONTRIBUTED WORKSHOPS - SESSION 1 1
	WD1	NICE IDEAS FACING A REALITY CHECK: PRODUCING ECONOMIC EVIDENCE FOR THE UK APPRAISAL PROCESS Hutton J, Chambers M, MEDTAP International, London, UK
	WD2	OVERCOMING BARRIERS TO OUTCOMES RESEARCH IN A MANAGED CARE SETTING: AN INTERNATIONAL PERSPECTIVE Brixner D1, Miller B2, Grueger J3, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 2Kaiser Permanente, The Permanente Medical Group, Inc., Oakland, CA, USA; 3Novartis Pharma AG, Basel, Switzerland
	WE1	ADAPTING INTERNATIONALLY DEVELOPED EVIDENCE-BASED GUIDELINES FOR LOCAL USE: A CASE STUDY IN SEIZURE DISORDER Gunter M1, Ruta DA2, Menz JM3, 1Lovelace Clinic Foundation, Albuquerque, NM, USA; 2Ninewells Hospital and Medical School, Dundee, Scotland; 3Novartis Pharmaceuticals, East Hanover, NJ, USA
	WM1	STRUCTURED DECISION MAKING IN PHARMACOECONOMIC STUDIES: A COMPARISON AND CRTIQUE Evans C1, Saal G2, Crawford B1, 1MAPI Values, Boston, MA, USA; 2MAPI Values, Cheshire, UK
	WM3	CRITICALLY EVALUATING ECONOMIC MODELS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) USE AND GASTRO-INTESTINAL COMPLICATIONS Annemans L12, Vanoverbeke N2, 1Free University of Brussels (VUB), Brussels, Belgium; 2HEDM, Mechelen, Belgium
9.30 - 10.25	CONTRIBUTED WORKSHOPS - SESSION 2
	WD3	POTENTIAL FOR BIAS WHEN USING CLINICAL TRIAL ADVERSE EVENT RATES TO MODEL TOXICITY COSTS Neighbors D, Research Triangle Institute, Research Triangle Park, NC, USA
	WD4	PERFORMING OUTCOMES RESEARCH FROM AN EMPLOYER'S PERSPECTIVE Halpern M1, Khan Z2, Rentz A1, Shikiar R3, 1MEDTAP International, Bethesda, MD, USA; 2Glaxo Wellcome Inc., Research Triangle Park, NC, USA; 3MEDTAP International, Seattle, WA, USA
	WM2	DERIVING UNIT COST DATA FOR MULTINATIONAL ECONOMIC EVALUATIONS Hutton J, Constenla D, Hollenbach F, MEDTAP International, London, UK
	WM4	COMPARING WILLINGNESS TO PAY ATTITUDES OF PATIENTS AND THE GENERAL POPULATION Annemans L12, Jegers M1, De Clercq H1, De Graeve D3, 1Free University of Brussels (VUB), Brussels, Belgium; 2HEDM, Mechelen, Belgium; 3University of Antwerp (UFSIA), Antwerpen, Belguim
	WP2	DEVELOPMENT OF GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS: FROM NETHERLANDS TO THE REST OF EUROPE Munro V1, Nuijten M2, 1MEDTAP International, London, UK; 2MEDTAP International, Amsterdam, The Netherlands
10:30 - 11.30	EXHIBITORS HOUR AND FINAL VIEWING OF POSTER PRESENTATIONS
11.30 - 12.30	PLENARY SESSION A Report from The National Institute for Clinical Excellence (NICE) Presented by: Sir Michael Rawlins MD, FRCP Professor of Clinical Pharmacology, Wolfsoni Unit of Clinical Pharmacology, University of Newcastle, Newcastle upon Tyne, United Kingdom
12:30 - 13.30	LUNCH & EXHIBITIONS
13:30 - 14.30	SECOND GENERAL SESSION — DEVELOPING CONSENSUS ON EVIDENCE-BASED TREATMENT GUIDELINES: REPORTS OF THE TREATMENT GUIDELINE WORK SESSIONS Prophylactic Use of Antibiotics in Surgical Procedures developed by the Scottish Intercollegiate Guideline Network (SIGN) Report Presenter: Leonid S. Stratchounski MD, PhD, Head, Department of Clinical Pharmacology and Antimicriobial Chemotherapy, Smolensk State Medical Academy, Smolensk, Russia Guidelines for the Treatment of Hypertension issued by the Spanish Ministry of Health Report Presenter: Martin Eccles MD, FRCP, Professor of Clinical Effectiveness, Centre for Health Services Research, University of Newcastle, Newcastle upon Tyne, United Kingdom Guidelines for the Treatment of Hypercholesterolemia issued by The Netherlands Ministry of Health Report Presenter: Thomas Szucs MD, MBA, Abteilungsleiter, Zurich, Switzerland
14:30 - 14.40	BREAK
14.40 - 15.35	CONTRIBUTED WORKSHOPS - SESSION 3
	WD5	MEASUREMENT OF PATIENT SATISFACTION WITH MEDICAL TREATMENT Trudeau-Vanhems E1, Marquis P1, Evans C2, 1MAPI VALUES, Lyon, France; 2MAPI VALUES, Boston, MA, USA
	WD7	HOW CAN OUTCOMES OF TREATMENT BE MEASURED FOR MEDICINES AVAILABLE THROUGH COMMUNITY PHARMACIES McNaughton D, MacDonald T, Medicines Monitoring Unit, Dundee University, Ninewells Hospital, Dundee, Scotland
	WM5	BEYOND THE STATIC: IMPORTANCE OF EPIDEMIOLOGICAL MODELING IN PHARMACOECONOMICS STUDIES IN INFECTIOUS DISEASES Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA
	WM6	POOLING MANAGED CARE ADMINISTRATIVE DATA FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH Goodman M1, Hornbrook M2, Fishman P3, 1HealthPartners Research Foundation, Minneapolis, MN, USA; 2Kaiser Center for Health Research, Portland, OR, USA; 3Group Health Cooperative Center for Health Studies, Seattle, WA, USA
	WP3	BUILDING A PHARMACOECONOMIC STRATEGY FOR A PRODUCT Nuijten M1, Chambers M2, 1MEDTAP International, Amsterdam, The Netherlands; 2MEDTAP International, London, UK
15.35 - 15.45	BREAK
15.45 - 16.40	CONTRIBUTED WORKSHOPS - SESSION 4
	WD6	IMPLEMENTING ASSESSMENT OF SEVERITY TO GUIDE TREATMENT DECISIONS AND TO OPTIMIZE OUTCOMES Wright A1, Lipton RB2, Stewart WF2, Ricci JA2, 1Advance Paradigm, Hunt Valley, MD, USA; 2IMR, Towson, MD, USA
	WD8	CASE-CROSSOVER DESIGN: A SOLUTION TO SELECTION BIAS? Donnan PT, Medicines Monitoring Unit, Department of Clinical Pharmacology, University of Dundee, Dundee, Scotland
	WM7	THE COMPARABILITY AND TRANSFERABLILTY OF DIRECT MEDICAL COSTS IN INTERNATIONAL PHARMACOECONOMIC STUDIES Rovira J1, Antonanzas F1, Girod I2, Arnould B2, Crawford B3, Evans C3, 1Universidad de la Rioja, Barcelona, Spain; 2Mapi Values, Lyon, France; 3Mapi Values, Boston, MA, USA
	WM9	COMPARING SOFTWARE AND INTERNET OPTIONS IN PHARMACOECONOMIC APPLICATIONS: SPREADSHEETS, DECISION TREES AND EDUCATIONAL TOOLS McGhan WF, University of the Sciences in Philadelphia, Philadelphia, PA, USA
	WDK1	DEVELOPMENT OF AN ELECTRONIC TOOL FOR EVALUATING NON-STATIC PATIENT POPULATIONS USING THE FLOATING MARKOV MATRIX ANALYSIS Brandman J, Day D, Ambegaonkar A, Livengood K, Lubowski TJ, Nobles-Knight D, Van Vleet J, Woon J, Yamaga C, Clinical Pharmacy Outcomes Research, Pfizer Inc., New York, NY, USA
	WE3	CURRENT REQUIREMENTS FOR HEALTH ECONoMIC AND QUALITY OF LIFE INFORMATION IN CENTRAL EUROPE, EASTERN EUROPE AND RUSSIA Nuijten M1, Halpern M2, Kiebert3, Hutton J3, 1MEDTAP International, Amsterdam, The Netherlands; 2MEDTAP International, Washington, DC, USA; 3MEDTAP International, London, UK Vorobyev PA1, Vyalkov AI1, Katlinsky AV1, Kobina SA2, Belousov YB3, Novolodsky VM3, 1Moscow Medical Academy, Moscow, Russia; 2Rhône-Poulenc Rorer, Moscow, Russia; 3Russian State Medical University, Moscow, Russia
16.40 - 17.00	BREAK
17.00 - 17.30	KEYNOTE ADDRESS Equity and Quality in Healthcare Presented by: Sir David Carter MD, FRCP, Chief Medical Officer, Scottish Executive Health Department, Edinburgh, Scotland This keynote address will present the decision-making processes in the United Kingdom's National Health Service (NHS) to assure quality healthcare for all.
17.30 - 18.30	ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP MEETING QofL SIG Leaders: Paul Kind PhD, University of York, York, United Kingdom and Patrick Marquis MD, MAPI VALUES, Lyon, France
20.00 - 24.00	TRADITIONAL SCOTTISH "CEILIDH" PARTY featuring The Norloch Ceilidh Band Sponsored by: MEMO, University of Dundee, Dundee, Scotland